Potential of the Angiotensin Receptor Blockers (ARBs) Telmisartan, Irbesartan, and Candesartan for Inhibiting the HMGB1/RAGE Axis in Prevention and Acute Treatment of Stroke

Potential of the Angiotensin Receptor Blockers (ARBs) Telmisartan, Irbesartan, and Candesartan for Inhibiting the HMGB1/RAGE Axis in Prevention and Acute Treatment of Stroke

Stroke is a major cause of mortality and disability worldwide. The main cause of stroke is atherosclerosis, and the most common risk factor for atherosclerosis is hypertension. Therefore, antihypertensive treatments are recommended for the prevention of stroke. Three angiotensin receptor blockers (A...

Full description

Bibliographic Details
Main Authors:	Eiichiro Tanaka, Yoshinaka Murai, Ikuro Maruyama, Ko-ichi Kawahara, Naoki Miura, Yoko Morimoto-Yamashita, Salunya Tancharoen, Takashi Ito, Kiyoshi Kikuchi
Format:	Article
Language:	English
Published:	MDPI AG 2013-09-01
Series:	International Journal of Molecular Sciences
Subjects:	stroke telmisartan irbesartan candesartan high mobility group box 1 receptor for advanced glycation end-products
Online Access:	http://www.mdpi.com/1422-0067/14/9/18899

Similar Items

Correction: Kikuchi, K., et al., Potential of the Angiotensin Receptor Blockers (ARBs) Telmisartan, Irbesartan, and Candesartan for Inhibiting the HMGB1/RAGE Axis in Prevention and Acute Treatment of Stroke. Int. J. Mol. Sci. 2013, 14, 18899–18924.
by: Kiyoshi Kikuchi, et al.
Published: (2014-03-01)

A Fast and Validated Reversed-Phase HPLC Method for Simultaneous Determination of Simvastatin, Atorvastatin, Telmisartan and Irbesartan in Bulk Drugs and Tablet Formulations
by: Hassan A. Alhazmi, et al.
Published: (2017-12-01)

Solid lipid nanoparticles of irbesartan: preparation, characterization, optimization and pharmacokinetic studies
by: Deepthi Soma, et al.
Published: (2017-04-01)

Candesartan in treating hypertension
by: L O Minushkina
Published: (2014-03-01)

Bio-Distribution and Pharmacokinetics of Topically Administered γ-Cyclodextrin Based Eye Drops in Rabbits
by: Martin Kallab, et al.
Published: (2021-05-01)

IRBESARTAN IN THE CLINICAL PRACTICE
by: V. I. Podzolkov, et al.
Published: (2015-09-01)

Comparative bioavailability of a newly developed Irbesartan 300 mg containing preparation
by: Petrov Andrey D., et al.
Published: (2018-01-01)

Telmisartan and cardioprotection
by: McFarlane S
Published: (2011-11-01)

Observational study on patients’ compliance with Irbesartan in essential hypertension “I Comply”
by: K. Leon, et al.
Published: (2014-03-01)

Changes of Necroptosis in Irbesartan Medicated Cardioprotection in Diabetic Rats
by: Xu Q, et al.
Published: (2021-09-01)

CANDESARTAN IN CARDIOLOGY PRACTICE
by: N. A. Dzhaiani
Published: (2017-12-01)

Simultaneous Analysis of Irbesartan and Hydrochlorothiazide: An Improved HPLC Method with the Aid of a Chemometric Protocol
by: Predrag Stankovic, et al.
Published: (2012-03-01)

Effect of Irbesartan on Chemerin in the Renal Tissues of Diabetic Rats
by: Qiu-Xia Yu, et al.
Published: (2015-09-01)

HPLC method with monolithic column for simultaneous determination of irbesartan and hydrochlorothiazide in tablets
by: Alanazi Amer M., et al.
Published: (2014-06-01)

The Effects of Telmisartan and Losartan on Insulin Sensitivity
by: Okan Bakıner, et al.
Published: (2013-12-01)

No pharmacokinetic interactions between candesartan and amlodipine following multiple oral administrations in healthy subjects
by: Kim JR, et al.
Published: (2018-08-01)

Differential clinical profile of candesartan compared to other angiotensin receptor blockers
by: Zimlichman R
Published: (2011-12-01)

Renoprotective effect of irbesartan in a rat model of gentamicin-induced nephrotoxicity: Role of oxidative stress
by: Hayder M. Al-Kuraishy, et al.
Published: (2019-07-01)

Clinical case: Effectiveness of combined therapyOrlistat and Irbesartan at the Metabolic syndrome patient with Arterial hypertension
by: K P Ivanov, et al.
Published: (2009-03-01)

Efecto de telmisartan sobre marcadores del remodelado óseo en pacientes hipertensos Telmisartan effect's on remodelling bone markers in hypertensive patients
by: J. L. Pérez-Castrillón, et al.
Published: (2012-02-01)

Effect of Huangqi injection combined with irbesartan on microcirculation and CTGF in patients with early DN
by: Yu-Jun Ren
Published: (2016-11-01)

Investigation of the effects of tadalafil and telmisartan in bleomycin-induced pulmonary fibrosis on rats
by: Nuri İhsan Kalyoncu, et al.
Published: (2020-08-01)

Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients withtype 2 diabetes mellitus and mild hypertension:a sequential, randomized, double-blind clinical trial
by: - Giuseppe Derosa, et al.
Published: (2009-03-01)

Nanocrystalline Suspensions of Irbesartan Enhance Oral Bioavailability by Improving Drug Solubility and Leading Endocytosis Uptake into the Intestine
by: Saori Deguchi, et al.
Published: (2021-09-01)

The Antihypertensive Efficacy of Chlorthalidone and Telmisartan in Indian Hypertensive Patients who were Uncontrolled with Hydrochlorothiazide and Telmisartan Combination-A Prospective and an Open Label Study
by: Suresh V Sagarad, et al.
Published: (2014-04-01)

Cost Effectiveness Kombinasi Antihipertensi Candesartan-Bisoprolol dan Candesartan-Amlodipin Pada Pasien Rawat Jalan Penderita Hipertensi
by: Eny Nurhikma, et al.
Published: (2019-12-01)

Pharmacokinetic interaction between irbesartan and Orthosiphon stamineus extract in rat plasma
by: Nur Meilis, et al.
Published: (2016-02-01)

Comparative Study of High Dose Mono-Therapy of Amlodipine or Telmisartan, and Their Low Dose Combination in Mild to Moderate Hypertension
by: Jaswant Goyal, et al.
Published: (2014-06-01)

Effect of calcium dobesilate combined with irbesartan therapy on proteinuria and serum inflammatory mediator levels in early diabetic nephropathy
by: Jing Hou
Published: (2016-09-01)

Candesartan in the prevention of cardiovascular catastrophes: emphasis on the pre-vention of stroke
by: Oksana Mikhaylovna Drapkina, et al.
Published: (2009-12-01)

Candesartan effectiveness in essential arterial hypertension and renal arterial hypertension
by: N. M. Chikhladze, et al.
Published: (2008-12-01)

Use of angiotensin receptor blockers in cardiovascular protection. Current evidence and future directions
by: M. A. Munger
Published: (1970-01-01)

Effect of irbesartan hydrochlorothiazide on endothelial function, hemodynamics and inflammatory response in hypertensive patients
by: Chen-Yan Ge, et al.
Published: (2018-08-01)

A multicenter, open-label study of the efficacy and safety of telmisartan in mild to moderate hypertensive patients
by: Plavnik Frida Liane, et al.
Published: (2002-01-01)

Morphological changes in tissues of organs in rats with arterial hypertension (SHR) with treatment of hypotensive medicines (with ramipril and candesartan) in combination with corvitin
by: Alena Marushchak, et al.
Published: (2020-02-01)

Candesartan cilexetil in cardiovascular prevention
by: A. Ya. Ivleva
Published: (2007-12-01)

Formulation and Bioavailability of Novel Mucoadhesive Buccal Films for Candesartan Cilexetil in Rats
by: Omar Y. Mady, et al.
Published: (2021-08-01)

Irbesartan attenuates gentamicin-induced nephrotoxicity in rats through modulation of oxidative stress and endogenous antioxidant capacity
by: Hayder M Al-kuraishy, et al.
Published: (2020-01-01)

Efficacy of a fixed dose combination of irbesartan and atorvastatin (Rovelito®) in Korean adults with hypertension and hypercholesterolemia
by: Ihm SH, et al.
Published: (2019-02-01)

Efficacy of irbesartan in arterial hypertension and metabolic syndrome
by: O D Ostroumova, et al.
Published: (2013-06-01)